MAPT and Alzheimer disease: While most AD therapies have focused on neuronal or microglial mechanisms,22,61 our data suggest that targeting downstream consequences of tau aggregation, such as biomechanical dysregulation in astrocytes, may offer a complementary approach to restore lost function.